Skip to main content
Top
Published in: AIDS and Behavior 4/2010

Open Access 01-08-2010 | Original Research

Transportation Costs Impede Sustained Adherence and Access to HAART in a Clinic Population in Southwestern Uganda: A Qualitative Study

Authors: David M. Tuller, David R. Bangsberg, Jude Senkungu, Norma C. Ware, Nneka Emenyonu, Sheri D. Weiser

Published in: AIDS and Behavior | Issue 4/2010

Login to get access

Abstract

The cost of transportation for monthly clinic visits has been identified as a potential barrier to antiretroviral (ARV) adherence in sub-Saharan Africa and elsewhere, although there is limited data on this issue. We conducted open-ended interviews with 41 individuals living with HIV/AIDS and attending a clinic in Mbarara, Uganda, to understand structural barriers to ARV adherence and clinical care. Almost all respondents cited the need to locate funds for the monthly clinic visit as a constant source of stress and anxiety, and lack of money for transportation was a key factor in cases of missed doses and missed medical appointments. Participants struggled with competing demands between transport costs and other necessities such as food, housing and school fees. Our findings suggest that transportation costs can compromise both ARV adherence and access to care. Interventions that address this barrier will be important to ensure the success of ARV programs in sub-Saharan Africa.
Literature
go back to reference Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (London, England), 14(4), 357–366. doi:10.1097/00002030-200003100-00008. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (London, England), 14(4), 357–366. doi:10.​1097/​00002030-200003100-00008.
go back to reference Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., et al. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (London, England), 15(9), 1181–1183. doi:10.1097/00002030-200106150-00015. Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., et al. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (London, England), 15(9), 1181–1183. doi:10.​1097/​00002030-200106150-00015.
go back to reference Behforouz, H. L., Farmer, P. E., & Mukherjee, J. S. (2004). From directly observed therapy to accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clinical Infectious Diseases, 38(Supp 5), S429–S436. doi:10.1086/421408.CrossRefPubMed Behforouz, H. L., Farmer, P. E., & Mukherjee, J. S. (2004). From directly observed therapy to accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clinical Infectious Diseases, 38(Supp 5), S429–S436. doi:10.​1086/​421408.CrossRefPubMed
go back to reference Byakika-Tusiime, J., Oyugi, J. H., Tumwikirize, W. A., Katabira, E. T., Mugyenyi, P. N., & Bangsberg, D. R. (2005). Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. International Journal of STD and AIDS, 16(1), 38–41. doi:10.1258/0956462052932548.CrossRefPubMed Byakika-Tusiime, J., Oyugi, J. H., Tumwikirize, W. A., Katabira, E. T., Mugyenyi, P. N., & Bangsberg, D. R. (2005). Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. International Journal of STD and AIDS, 16(1), 38–41. doi:10.​1258/​0956462052932548​.CrossRefPubMed
go back to reference Carlucci, J. G., Kamanga, A., Sheneberger, R., Shepherd, B. E., Jenkins, C. A., Spurrier, J., et al. (2008). Predictors of adherence to antiretroviral therapy in rural Zambia. Journal of Acquired Immune Deficiency Syndromes, 47(5), 615–622. doi:10.1097/QAI.0b013e318165dc25.CrossRefPubMed Carlucci, J. G., Kamanga, A., Sheneberger, R., Shepherd, B. E., Jenkins, C. A., Spurrier, J., et al. (2008). Predictors of adherence to antiretroviral therapy in rural Zambia. Journal of Acquired Immune Deficiency Syndromes, 47(5), 615–622. doi:10.​1097/​QAI.​0b013e318165dc25​.CrossRefPubMed
go back to reference Crane, J. T., Kawuma, A., Oyugi, J. H., Byakika, J. T., Moss, A., Bourgois, P., et al. (2006). The price of adherence: Qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS and Behavior, 10(4), 437–442. doi:10.1007/s10461-006-9080-z.CrossRefPubMed Crane, J. T., Kawuma, A., Oyugi, J. H., Byakika, J. T., Moss, A., Bourgois, P., et al. (2006). The price of adherence: Qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS and Behavior, 10(4), 437–442. doi:10.​1007/​s10461-006-9080-z.CrossRefPubMed
go back to reference Creswell, J. (1998). Qualitative inquiry and research design: Choosing among five traditions. Thousand Oaks, CA: Sage Publications, Inc. Creswell, J. (1998). Qualitative inquiry and research design: Choosing among five traditions. Thousand Oaks, CA: Sage Publications, Inc.
go back to reference Hardon, A. P., Akurut, D., Comoro, C., Ekezie, C., Irunde, H. F., Gerrits, T., et al. (2007). Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa. AIDS Care, 19(5), 658–665. doi:10.1080/09540120701244943.CrossRefPubMed Hardon, A. P., Akurut, D., Comoro, C., Ekezie, C., Irunde, H. F., Gerrits, T., et al. (2007). Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa. AIDS Care, 19(5), 658–665. doi:10.​1080/​0954012070124494​3.CrossRefPubMed
go back to reference Ivers, L. C., Kendrick, D., & Doucette, K. (2005). Efficacy of antiretroviral therapy programs in resource-poor settings: A meta-analysis of the published literature. Clinical Infectious Diseases, 41(2), 217–224. doi:10.1086/431199.CrossRefPubMed Ivers, L. C., Kendrick, D., & Doucette, K. (2005). Efficacy of antiretroviral therapy programs in resource-poor settings: A meta-analysis of the published literature. Clinical Infectious Diseases, 41(2), 217–224. doi:10.​1086/​431199.CrossRefPubMed
go back to reference Koenig, S. P., Leandre, F., & Farmer, P. E. (2004). Scaling-up HIV treatment programmes in resource-limited settings: The rural Haiti experience. AIDS (London, England), 18(Suppl. 3), S21–S25. doi:10.1097/00002030-200406003-00005. Koenig, S. P., Leandre, F., & Farmer, P. E. (2004). Scaling-up HIV treatment programmes in resource-limited settings: The rural Haiti experience. AIDS (London, England), 18(Suppl. 3), S21–S25. doi:10.​1097/​00002030-200406003-00005.
go back to reference Kumarasamy, N., Safren, S. A., Raminani, S. R., Pickard, R., James, R., Krishnan, A. K., et al. (2005). Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: A qualitative study. AIDS Patient Care and STDs, 19(8), 526–537. doi:10.1089/apc.2005.19.526.CrossRefPubMed Kumarasamy, N., Safren, S. A., Raminani, S. R., Pickard, R., James, R., Krishnan, A. K., et al. (2005). Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: A qualitative study. AIDS Patient Care and STDs, 19(8), 526–537. doi:10.​1089/​apc.​2005.​19.​526.CrossRefPubMed
go back to reference Laurent, C., Diakhate, N., Gueye, N. F., Toure, M. A., Sow, P. S., Faye, M. A., et al. (2002). The Senegalese government’s highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS (London, England), 16(10), 1363–1370. doi:10.1097/00002030-200207050-00008. Laurent, C., Diakhate, N., Gueye, N. F., Toure, M. A., Sow, P. S., Faye, M. A., et al. (2002). The Senegalese government’s highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS (London, England), 16(10), 1363–1370. doi:10.​1097/​00002030-200207050-00008.
go back to reference Mills, E. J., Nachega, J. B., Bangsberg, D. R., Singh, S., Rachlis, B., Wu, P., et al. (2006). Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine, 3(11), e438. doi:10.1371/journal.pmed.0030438.CrossRefPubMed Mills, E. J., Nachega, J. B., Bangsberg, D. R., Singh, S., Rachlis, B., Wu, P., et al. (2006). Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine, 3(11), e438. doi:10.​1371/​journal.​pmed.​0030438.CrossRefPubMed
go back to reference Mshana, G. H., Wamoyi, J., Busza, J., Zaba, B., Changalucha, J., Kaluvya, S., et al. (2006). Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: A qualitative study of early rural referrals to the national program. AIDS Patient Care and STDs, 20(9), 649–657. doi:10.1089/apc.2006.20.649.CrossRefPubMed Mshana, G. H., Wamoyi, J., Busza, J., Zaba, B., Changalucha, J., Kaluvya, S., et al. (2006). Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: A qualitative study of early rural referrals to the national program. AIDS Patient Care and STDs, 20(9), 649–657. doi:10.​1089/​apc.​2006.​20.​649.CrossRefPubMed
go back to reference Mukherjee, J. S., Ivers, L., Leandre, F., Farmer, P., & Behforouz, H. (2006). Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. Journal of Acquired Immune Deficiency Syndromes, 43(Suppl. 1), S123–S126. doi:10.1097/01.qai.0000248348.25630.74.PubMed Mukherjee, J. S., Ivers, L., Leandre, F., Farmer, P., & Behforouz, H. (2006). Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. Journal of Acquired Immune Deficiency Syndromes, 43(Suppl. 1), S123–S126. doi:10.​1097/​01.​qai.​0000248348.​25630.​74.PubMed
go back to reference Orrell, C., Bangsberg, D. R., Badri, M., & Wood, R. (2003). Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (London, England), 17(9), 1369–1375. doi:10.1097/00002030-200306130-00011. Orrell, C., Bangsberg, D. R., Badri, M., & Wood, R. (2003). Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (London, England), 17(9), 1369–1375. doi:10.​1097/​00002030-200306130-00011.
go back to reference Oyugi, J. H., Byakika-Tusiime, J., Charlebois, E. D., Kityo, C., Mugerwa, R., Mugyenyi, P., et al. (2004). Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes, 36(5), 1100–1102. doi:10.1097/00126334-200408150-00014.CrossRefPubMed Oyugi, J. H., Byakika-Tusiime, J., Charlebois, E. D., Kityo, C., Mugerwa, R., Mugyenyi, P., et al. (2004). Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes, 36(5), 1100–1102. doi:10.​1097/​00126334-200408150-00014.CrossRefPubMed
go back to reference Safren, S. A., Kumarasamy, N., James, R., Raminani, S., Solomon, S., & Mayer, K. H. (2005). ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care, 17(7), 853–862. doi:10.1007/b138963.PubMed Safren, S. A., Kumarasamy, N., James, R., Raminani, S., Solomon, S., & Mayer, K. H. (2005). ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care, 17(7), 853–862. doi:10.​1007/​b138963.PubMed
go back to reference Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhema, J., et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 34(3), 281–288. doi:10.1097/00126334-200311010-00004.CrossRefPubMed Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhema, J., et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 34(3), 281–288. doi:10.​1097/​00126334-200311010-00004.CrossRefPubMed
go back to reference Wood, E., Hogg, R. S., Yip, B., Quercia, R., Harrigan, P. R., O’Shaughnessy, M. V., et al. (2003). Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. The Journal of Infectious Diseases, 188(10), 1421–1425. doi:10.1086/379201.CrossRefPubMed Wood, E., Hogg, R. S., Yip, B., Quercia, R., Harrigan, P. R., O’Shaughnessy, M. V., et al. (2003). Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. The Journal of Infectious Diseases, 188(10), 1421–1425. doi:10.​1086/​379201.CrossRefPubMed
Metadata
Title
Transportation Costs Impede Sustained Adherence and Access to HAART in a Clinic Population in Southwestern Uganda: A Qualitative Study
Authors
David M. Tuller
David R. Bangsberg
Jude Senkungu
Norma C. Ware
Nneka Emenyonu
Sheri D. Weiser
Publication date
01-08-2010
Publisher
Springer US
Published in
AIDS and Behavior / Issue 4/2010
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-009-9533-2

Other articles of this Issue 4/2010

AIDS and Behavior 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.